Source: iQoncept / Shutterstock
Lyra Therapeutics (NASDAQ:LYRA) has recently revealed its performance figures for the fourth quarter of 2023.
- Lyra Therapeutics posted earnings per share of -22 cents, surpassing the projected EPS of -31 cents by analysts.
- The company’s revenue totaled $146,000, falling significantly short by 62.56% compared to the anticipated revenue of $390,000.
Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/lyra-stock-earnings-lyra-therapeutics-for-q4-of-2023/.
©2024 InvestorPlace Media, LLC
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
